# A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

> **NCT03797456** · PHASE2 · COMPLETED · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 111 (actual)

## Conditions studied

- MZL

## Interventions

- **DRUG:** ICP-022

## Key facts

- **NCT ID:** NCT03797456
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2023-12-27
- **Final completion:** 2024-02-06
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797456, "A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03797456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*